Public Reimbursement of Trikafta Nears in Canada

Public Reimbursement of Trikafta Nears in Canada

306598

Public Reimbursement of Trikafta Nears in Canada

Vertex Pharmaceuticals has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA), which is an agreement in principle to extend public reimbursement to Trikafta, a triple-combination therapy for eligible cystic fibrosis (CF) patients. The extension adds to the letter of intent (LOI) with the pCPA for the cystic fibrosis treatments Orkambi and Kalydeco, also marketed by Vertex. The pCPA negotiates prices of medications for the country’s provinces and territories, which control and manage their…

You must be logged in to read/download the full post.